Skip to main content
. 2013 Sep;57(9):4543–4546. doi: 10.1128/AAC.00259-13

Table 2.

Relevant characteristics of the 24 LSA strains

Strain (hospitala) Speciesb Antibiotypec MLS genotyped CLI
 PT
MIC (μg/ml) Susceptibilitye MIC (μg/ml) Susceptibility
S3 (A) S. aureus Oxar Kanr Tobr Pefr Lini vga(A) allele 1 0.25 S 0.75 S
S4 (A) S. aureus Oxar Kanr Tobr Pefr Lini vga(A)v 0.25 S 0.75 S
S5 (A) S. aureus Oxar Kanr Tobr Genr Pefr Sulr Rifr Linr vga(A)v 1 R 0.5 S
S6 (E) S. aureus Oxar Kanr Tobr Pefr Lini vga(A)v 0.25 S 0.5 S
S7 (D) S. epidermidis Penr Linr vga(A) allele 2 0.75 R 0.19 S
S8 (B) S. aureus Oxar Pefr Lini vga(A)v 0.25 S 0.38 S
S9 (B) S. aureus Oxar Tetr Sxtr Lini vga(A)v 0.5 I 0.5 S
S10 (B) S. aureus Oxar Kanr Tobr Pefr Lini vga(A)v 0.25 S 0.5 S
S11 (B) S. aureus Penr Linr lnu(A) + vga(A) 0.19 S 0.38 S
S12 (C) S. aureus Oxar Kanr Tobr Pefr Lini vga(A)v 0.25 S 0.5 S
S13 (B) S. aureus Penr Kanr Tobr Tetr Sxtr Linr lnu(A) + vga(A) 0.19 S 0.38 S
S14 (A) S. sciuri Lini Unknown 0.38 S 0.75 S
S15 (E) S. epidermidis Oxar Kanr Tobr Genr Pefr Sxtr Lini vga(A)v 0.5 I 0.75 S
S17 (C) S. aureus Oxar Pefr Sulr Lini vga(A) 0.19 S 0.5 S
S19 (C) S. epidermidis Oxar Kanr Tobr Genr Pefr Sxtr Lini vga(A)v 0.5 I 0.5 S
S22 (E) S. aureus Oxar Kanr Tobr Genr Pefr Sxtr Lini vga(A)v 0.5 I 0.5 S
S23 (E) Staphylococcus hominis Oxar Kanr Tobr Genr Pefr Sxtr Teir Lini vga(A) 0.25 S 0.5 S
S25 (D) S. aureus Oxar Kanr Tobr Pefr Lini vga(A)v 0.25 S 0.75 S
S26 (D) S. epidermidis Oxar Kanr Tobr Genr Pefr Sxtr Lini vga(A)v 0.5 I 1 S
S27 (B) S. aureus Oxar Kanr Tobr Pefr Lini vga(A)v + vat(A) 0.25 S 12 R
S29 (B) S. aureus Oxar Kanr Tobr Pefr Linr vga(A)v 0.5 I 1 S
S31 (C) S. haemolyticus Fosr Linr vga(A)LC 3 R 0.38 S
S33 (A) S. epidermidis Oxar Kanr Tobr Genr Pefr Sxtr Lini vga(A)v 0.5 I 0.75 S
S36 (E) S. epidermidis Oxar Kanr Tobr Genr Pefr Sxtr Fusi Lini vga(A)v 0.5 I 0.5 S
a

Hospitals at which strains were collected: A, HIA Val-de-Grace, Paris, France; B, HIA Robert Picqué, Bordeaux, France; C, HIA Clermont-Tonerre, Brest, France; D, HIA Percy, Clamart, France; E, HIA Legouest, Metz, France.

b

Species identification was done by 16S rRNA gene sequencing.

c

Antibiotype was determined according to EUCAST and CA-SFM table breakpoints. Fos, fosfomycin; Fus, fusidic acid; Gen, gentamicin; Kan, kanamycin; Lin, lincomycin; Oxa, oxacillin; Pef, pefloxacin; Pen, penicillin; Rif, rifampin; Sul, sulfonamide; Sxt, co-trimoxazole; Tei, teicoplanin; Tet, tetracyclin; Tob, tobramycin.

d

The macrolide-lincosamide-streptogramin (MLS) genotype was obtained by PCR amplification and direct sequencing.

e

S, susceptible; R, resistant; I, intermediate.